Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Operating Expenses of $17.8 million for Q1 2026, up 22.22% year-over-year from $14.6 million in Q1 2025, and up 29.52% quarter-over-quarter from $13.8 million in Q4 2025.
Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Operating Expenses for 7 consecutive years, with $17.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 22.22% year-over-year to $17.8 million; the TTM figure through Mar 2026 stood at $55.2 million (up 43.78% YoY), while the FY2025 annual figure was $52.0 million, up 81.8% from the prior year.
- Operating Expenses advanced to $17.8 million in Q1 2026 per IKT's latest filing, from $13.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $17.8 million in Q1 2026 and bottomed at $4.4 million in Q4 2022.
- Historically, Operating Expenses has averaged $8.1 million across 5 years, with a median of $5.1 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Expenses declined 20.07% — and 2025, when it surged 205.25%.
- Inhibikase Therapeutics' Operating Expenses stood at $4.4 million in 2022, then grew by 0.11% to $4.4 million in 2023, then jumped by 193.6% to $12.9 million in 2024, then rose by 6.55% to $13.8 million in 2025, then grew by 29.52% to $17.8 million in 2026.
- Business Quant data shows IKT's Operating Expenses at $17.8 million in Q1 2026, $13.8 million in Q4 2025, and $12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 21.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.05 Mn |
| Mar 31, 2026 | 17.84 Mn |
| Dec 31, 2025 | 13.78 Mn |
| Sep 30, 2025 | 12.77 Mn |
| Jun 30, 2025 | 10.83 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 12.93 Mn |
| Sep 30, 2024 | 5.83 Mn |
| Jun 30, 2024 | 5.05 Mn |
| Mar 31, 2024 | 4.78 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Sep 30, 2023 | 4.85 Mn |
| Jun 30, 2023 | 6.32 Mn |
| Mar 31, 2023 | 4.78 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2022 | 4.52 Mn |
| Jun 30, 2022 | 4.65 Mn |
| Mar 31, 2022 | 4.69 Mn |
| Dec 31, 2021 | 5.04 Mn |
| Sep 30, 2021 | 4.80 Mn |